Skip to main content

Advertisement

SpringerLink
Log in

The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie’s disease

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Aim

To determine the effectiveness of transdermal electromotive administration (TEA) of verapamil and dexamethasone in the treatment of Peyronie’s disease (PD).

Method

Totally, 51 patients with PD were prospectively included in the study. All patients were evaluated by history, subjective score scales, physical examination, photographs, and penile USG, before and after therapy. All patients were treated with TEA of the combination of verapamil and dexamethasone. The treatment plan included a total of 20 sessions (at 3-day intervals for a period of 2 months), each with a duration of 20 min. At the end of the study, improvements in penile plaques, penile deviation, pain on erection, and erectile dysfunction were determined.

Results

The findings in 41 of the 51 patients were eligible to present. Median patient age was 52 years. Median duration of disease at presentation was 8 months. Remarkable reduction in palpable plaques and in penile angulation was observed in 10 patients (24%) and 11 (26%) patients, respectively. There were significant decreases in median plaque volume from 72 mm2 to 45 mm2 (P < 0.001), and in median penile angulation from 25º to 15º (P < 0.001). Impaired sexual activity and pain on erection had completely resolved in 11 (55%) patients and in 16 (80%), respectively.

Conclusion

The results of our study have shown that TEA of the combination of verapamil and dexamethasone is a more effective therapy for improving subjective symptoms rather than objective symptoms. Therefore, we think that this treatment can be individualized according to the clinical features of PD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tefekli A, Kandirali E, Erol H, Alp T, Köksal T, Kadioğlu A (2001) Peyronie’s disease in men under age 40: characteristics and outcome. Int J Impot Res 13(1):18–23

    Article  PubMed  CAS  Google Scholar 

  2. Mulhall JP, Creech SD, Boorjian SA (2004) Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol 171(6 Pt 1):2350–2353

    Article  PubMed  Google Scholar 

  3. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U (2001) The prevalence of Peyronie’s disease: results of a large survey. BJU Int 88(7):727–730

    Article  PubMed  CAS  Google Scholar 

  4. Hellstrom WJ, Bivalacqua TJ (2000) Peyronie’s disease: etiology, medical, and surgical therapy. J Androl 21(3):347–354

    PubMed  CAS  Google Scholar 

  5. Devine CJ, Somers KD, Ladaga LE (1991) Peyronie’s disease: pathophysiology. Prog Clin Biol Res 370:355–358

    PubMed  Google Scholar 

  6. Levine LA, Merrick PF, Lee RC (1994) Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol 151(6):1522–1524

    PubMed  CAS  Google Scholar 

  7. Devine CJ, Somers KD, Jordan SG, Schlossberg SM (1997) Proposal: trauma as the cause of the Peyronie’s lesion. J Urol 157:285–290

    Article  PubMed  Google Scholar 

  8. Jarow JP, Lowe FC (1997) Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 158:1388–1390

    Article  PubMed  CAS  Google Scholar 

  9. Van de Water L (1997) Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie’s disease. J Urol 157:306–310

    Article  PubMed  Google Scholar 

  10. Bour H (1984) Current status of vitamin E. Rev Prat 34:1270–1271

    PubMed  CAS  Google Scholar 

  11. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP (1992) The treatment of Peyronie’s disease with tamoxifen. Br J Urol 70(6):648–651

    Article  PubMed  CAS  Google Scholar 

  12. Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF (1994) Is colchicine effective in Peyronie’s disease? A pilot study. Urology 44(2):291–295

    Article  PubMed  CAS  Google Scholar 

  13. Carson CC (1997) Potassium para-aminobenzoate for the treatment of Peyronie’s disease: is it effective? Tech Urol 3:135–139

    PubMed  CAS  Google Scholar 

  14. Fitkin J, Ho GT (1999) Peyronie’s disease: current management. Am Fam Physician 60(2):549–552

    PubMed  CAS  Google Scholar 

  15. Weidner W, Hauck EW, Schnitker J (2005) Peyronie’s Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol 47(4):530–535

    Article  PubMed  CAS  Google Scholar 

  16. Gelbard MK, Dorey F, James K (1990) The natural history of Peyronie’s disease. J Urol 144:1376–1379

    PubMed  CAS  Google Scholar 

  17. Tunuguntla HS (2001) Management of Peyronie’s disease—a review. World J Urol 19:244–250

    Article  PubMed  CAS  Google Scholar 

  18. Levine LA (1997) Treatment of Peyronie’s disease with intralesional verapamil injection. J Urol 158:1395–1399

    Article  PubMed  CAS  Google Scholar 

  19. Rehman J, Benet A, Melman A (1998) Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology 51:620–626

    Article  PubMed  CAS  Google Scholar 

  20. Levine LA, Goldman KE, Greenfield JM (2002) Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 168(2):621–625

    Article  PubMed  CAS  Google Scholar 

  21. Hellstrom WJ, Kendirci M, Matern R (2006) Single-blind, multicenter, placebo controlled paralel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol 176(1):394–398

    Article  PubMed  CAS  Google Scholar 

  22. Gelbard MK, James K, Riach P, Dorey F (1993) Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol 149(1):56–58

    PubMed  CAS  Google Scholar 

  23. Ludwig G (1991) Evaluation of conservative therapeutic approaches to Peyronie’s disease (fibrotic induration of the penis). Urol Int 47(4):236–239

    Article  PubMed  CAS  Google Scholar 

  24. Riedl CR, Plas E, Engelhardt P, Daha K, Pflüger H (2000) Iontophoresis for treatment of Peyronie’s disease. J Urol 163(1):95–99

    Article  PubMed  CAS  Google Scholar 

  25. Montorsi F, Salonia A, Guazzoni G (2000) Transdermal electromotive multi-drug administration for Peyronie’s disease: preliminary results. J Androl 21:85–90

    PubMed  CAS  Google Scholar 

  26. Di Stasi SM, Giannantoni A, Capelli G (2003) Transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. BJU Int 91:825–829

    Article  PubMed  CAS  Google Scholar 

  27. Di Stasi SM, Giannantoni A, Stephen RL (2004) A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol 171:1605–1608

    Article  PubMed  CAS  Google Scholar 

  28. Greenfield JM, Shah SJ, Levine LA (2007) Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol 177(3):972–975

    Article  PubMed  CAS  Google Scholar 

  29. Mulhall JP, Anderson MS, Lubrano T, Shankey TV (2002) Peyronie’s disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 14(5):397–405

    Article  PubMed  CAS  Google Scholar 

  30. Martin DJ, Badwan K, Parker M, Mulhall JP (2002) Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 168(6):2483–2485

    Article  PubMed  CAS  Google Scholar 

  31. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S (2002) A retrospective review of 307 men with Peyronie’s disease. J Urol 168(3):1075–1079

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, S.B. Diskapi Yildirim Beyazit Training and Research Hospital, Hosdere Caddesi, 115/72 Yukari-Ayranci, Ankara, 06550, Turkey

    Can Tuygun, Ugur Hakkı Ozok, Adnan Gucuk, I. Halil Bozkurt & M. Abdurrahim Imamoglu

Authors
  1. Can Tuygun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ugur Hakkı Ozok
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adnan Gucuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Halil Bozkurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Abdurrahim Imamoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Can Tuygun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tuygun, C., Ozok, U.H., Gucuk, A. et al. The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie’s disease. Int Urol Nephrol 41, 113–118 (2009). https://doi.org/10.1007/s11255-008-9408-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-008-9408-x

Keywords

Search

Navigation